ACM
Aquilo Capital Management Portfolio holdings
AUM
$37.1M
This Quarter Return
-8.42%
1 Year Return
-36.49%
3 Year Return
+1.32%
5 Year Return
+39.69%
10 Year Return
–
AUM
$110M
AUM Growth
+$110M
(-28%)
Cap. Flow
-$21.7M
Cap. Flow
% of AUM
-19.68%
Top 10 Holdings %
Top 10 Hldgs %
98.11%
Holding
13
New
–
Increased
3
Reduced
7
Closed
–
Top Buys
| 1 |
C4 Therapeutics
CCCC
|
$2.29M |
| 2 |
Kymera Therapeutics
KYMR
|
$1.82M |
| 3 |
Arrowhead Research
ARWR
|
$1.34M |
Top Sells
| 1 |
Merus
MRUS
|
$8.14M |
| 2 |
argenx
ARGX
|
$6.19M |
| 3 |
Genmab
GMAB
|
$4.32M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$3.51M |
| 5 |
Arvinas
ARVN
|
$2.65M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Arrowhead Research
ARWR
$3.51B
| $24.4M | 22.12% |
908,474
+50,000
| +6% | +$1.34M |
|
|
BPMC
2
DELISTED
Blueprint Medicines
BPMC
| $19M | 17.25% |
379,090
-69,897
| -16% | -$3.51M |
|
3
Regenxbio
RGNX
$464M
| $13.9M | 12.64% |
847,424
-22,690
| -3% | -$373K |
|
|
SLN
4
Silence Therapeutics
SLN
$225M
| $12.9M | 11.68% |
1,312,233
| – | – |
|
|
5
Kymera Therapeutics
KYMR
$2.87B
| $10.9M | 9.85% |
782,219
+130,894
| +20% | +$1.82M |
|
|
6
Merus
MRUS
$5.01B
| $10.1M | 9.19% |
430,109
-345,000
| -45% | -$8.14M |
|
|
7
Arvinas
ARVN
$572M
| $9.61M | 8.71% |
489,153
-134,788
| -22% | -$2.65M |
|
|
8
C4 Therapeutics
CCCC
$175M
| $3.7M | 3.35% |
1,990,334
+1,229,677
| +162% | +$2.29M |
|
|
9
Genmab
GMAB
$15.9B
| $1.84M | 1.67% |
52,148
-122,500
| -70% | -$4.32M |
|
|
10
argenx
ARGX
$42.8B
| $1.83M | 1.66% |
3,715
-12,600
| -77% | -$6.19M |
|
11
Olema Pharmaceuticals
OLMA
$417M
| $1.1M | 0.99% |
88,875
-161,125
| -64% | -$1.99M |
|
|
PVLA
12
Palvella Therapeutics, Inc. Common Stock
PVLA
$577M
| $984K | 0.89% |
3,303,190
| – | – |
|
13
iShares Russell 2000 ETF
IWM
$66.3B
| – | – |
0
| – | – |
|